MARKET INDEX
KOSPI5,459.46▲ 2.18%
KOSDAQ717.36▲ 2.99%
S&P 5007,592.40▼ 0.35%
NASDAQ25,366.09▼ 0.39%
USD/KRW1,335.34▲ 0.98 (+0.07%)
WTI Crude$88.42▼ 0.36%
BTC/USD$70,917▼ 0.64%
KOSPI5,459.46▲ 2.18%
KOSDAQ717.36▲ 2.99%
S&P 5007,592.40▼ 0.35%
NASDAQ25,366.09▼ 0.39%
USD/KRW1,335.34▲ 0.98 (+0.07%)
WTI Crude$88.42▼ 0.36%
BTC/USD$70,917▼ 0.64%
헤더 좌
헤더 우
BREAKING
MARKET Times 공식 배너

Anthropic IPO Sees Sixfold Oversubscription as Market Anticipates $19 Billion Index Inflow

AI firm Anthropic's IPO is seeing demand six times the offering size, with potential for the price to exceed $78 as investors eye massive post-listing index inflows.

Anthropic IPO Sees Sixfold Oversubscription as Market Anticipates $19 Billion Index Inflow
MTIMES Archive / Photo

Offering to raise up to $64.4 billion; speculation grows that price may exceed $78 range

Post-listing index-tracking fund inflows expected; existing shareholder sell-offs remain a key variable

Artificial intelligence firm Anthropic has reportedly received orders totaling approximately six times the available shares for its upcoming initial public offering (IPO). As institutional interest intensifies for the massive offering—which aims to raise up to $64.4 billion—speculation is mounting that the final offering price could exceed the top end of its target range. With the Nasdaq listing scheduled for the 19th, competition for shares is heating up, alongside expectations of significant follow-on buying from index-tracking funds.

On the 12th (local time), Reuters reported, citing Bloomberg, that orders for the Anthropic IPO have reached roughly six times the number of shares on offer. Underwriters are reportedly prioritizing allocations for existing investors, which may leave new institutional investors with smaller-than-requested allotments.

Anthropic plans to offer 825 million shares at a price range of $70 to $78 per share. At the top end of this range, the offering would raise approximately $64.4 billion, valuing the company at up to $1.4 trillion on a fully diluted basis. The company is also pursuing a separate $26 billion private placement involving major tech firms including Google, Nvidia, and AMD.

Given the stronger-than-expected demand, some market observers suggest the final price could surpass the $78 ceiling. However, these figures and conditions remain subject to change until the final pricing is confirmed.


Post-IPO Buying Pressure: $19 Billion in Index-Tracking Demand


Another defining feature of the Anthropic IPO is the potential for massive buying demand following the listing.

According to foreign media, Anthropic is expected to be included in major indices such as the Nasdaq 100, S&P Total Market Index, and FTSE US Index within 5 to 15 days of its debut. UK-based index data firm Intropic estimates that funds tracking these indices could generate approximately $19 billion in buying demand, representing roughly 28% of the total offering size.

ETFs and index funds typically adjust their portfolios by purchasing shares once a new stock is added to their tracked indices. Hedge funds and index arbitrageurs often attempt to front-run this demand. If institutional investors who failed to secure sufficient shares during the IPO enter the market after listing, their buying could overlap with index-related transactions.

A similar dynamic was observed during the SpaceX listing in June, where the stock price surged early on due to a combination of limited float and index-inclusion demand.

Anthropic’s public float is also limited to approximately 6% of its total shares. Retail investor interest is also high; market research firm Vanda Research projects that retail net buying on the first day could reach approximately $250 million, more than double the $118 million recorded during the SpaceX debut.

However, Intropic’s $19 billion estimate represents potential demand from index funds, not guaranteed capital inflows.


Existing Shareholders Eye Exit; Infrastructure Costs Loom


While new investors compete for shares, some existing stakeholders are looking to monetize their holdings.

According to Bloomberg, some investors are exploring ways to sell their stakes through special purpose vehicles (SPVs) prior to the listing. Unlike new investors betting on post-IPO gains, early backers view this IPO as an opportunity to recoup their investments.

Some shares will also be eligible for sale immediately after listing. According to an amended registration statement filed with the U.S. Securities and Exchange Commission (SEC), certain employees and former staff may sell up to 10% of their lock-up restricted shares starting from the first day of trading. Shares from the separate private placement are also reportedly exempt from standard lock-up restrictions. Nevertheless, it is unlikely that all eligible shares will hit the market simultaneously.

The company’s ability to sustain its high valuation through earnings growth remains a focal point. SEC filings show Anthropic’s third-quarter revenue reached approximately $16.96 billion, a 47% increase from the previous quarter, though this growth rate slowed from the 144% seen in the second quarter.

As of late October, the annualized revenue run rate stood at approximately $81 billion. Based on this internal metric—which annualizes the last 28 days of usage and subscription fees—the $1.4 trillion valuation represents roughly 17.3 times revenue.

Long-term commitments for computing and infrastructure spending total approximately $900.9 billion. Of this, about $451.6 billion is scheduled to be deployed by the end of 2030, with the remainder spread across 2031 to 2045. While some contracts include termination clauses, a shortfall in AI service demand could lead to prolonged cost burdens.

SpaceX’s stock price weakened as the lock-up expiration for existing shareholders approached following its initial post-listing surge. Anthropic faces a similar duality: buying demand awaiting index inclusion versus existing shareholders preparing to lock in profits. Whether the sixfold oversubscription translates into sustained price appreciation will be determined starting on the 19th.

MARKET Times

MTIMES Global Editorial Statement

This analysis is provided for international business intelligence and informational purposes only. It does not constitute investment advice or a solicitation to buy or sell securities. For inquiries regarding licensing or syndication, please contact [email protected].

← More in CorporateBack to Top ↑

Related Market & Corporate Intelligence

[Big Insight-Mer] CPI for September was announced. Let's take a look at the results[Big Insight-Mer] CPI for September was announced. Let's take a look at the resultsMezzion Pharma Targets First-ever Fontan Treatment Approval, Leveraging Clinical Expertise for Global CommercializationMezzion Pharma Targets First-ever Fontan Treatment Approval, Leveraging Clinical Expertise for Global CommercializationHLB Therapeutics CEO An Ki-hong: “RGN-259 Set to Become First-Line Choice for Neurotrophic Keratitis”HLB Therapeutics CEO An Ki-hong: “RGN-259 Set to Become First-Line Choice for Neurotrophic Keratitis”Global Phase 3 Watch: HLB Therapeutics Eyes $1.7B U.S. Neurotrophic Keratitis Market with November RGN-259 ReadoutGlobal Phase 3 Watch: HLB Therapeutics Eyes $1.7B U.S. Neurotrophic Keratitis Market with November RGN-259 Readout
HomeTOP10AlmatenPicksCorpAlgiten